Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 9 months ago
Share
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
282 patients around the world
Available in
Spain, Argentina, United States
GlaxoSmithKline
4
Research sites
282
Patients around the world
This study is for people with
Alzheimer disease
Requirements for the patient
To 85 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Consult
View site
Viamonte, Cdad. Autónoma de Buenos Aires, Argentina
View site
Consult
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Consult
View site
Av. Galvan 4102, CABA, Buenos Aires
View site
Consult
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
Consult
View site
Av. Cerviño 3375, CABA, Buenos Aires
View site
Consult
Fleni - sede Belgrano
Recruiting
Consult
View site
Montañeses 2325, CABA, Buenos Aires
View site
Consult
See details
Contact us
Contact us
Study
PROGRESS-AD
Sponsor
GlaxoSmithKline
Conditions
Alzheimer disease
Requirements
To 85 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06079190
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent